fm-ad.yaml

Name: Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)
Description: |
  The Foundation Medicine Adult Cancer Clinical Dataset (FM-AD) is a study conducted by Foundation
  Medicine Inc (FMI). Genomic profiling data for approximately 18,000 adult patients with a diverse
  array of cancers was generated using FoundationeOne, FMI's commercially available, comprehensive
  genomic profiling assay. This dataset contains open Clinical and Biospecimen data.
Documentation: |
  https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/foundation-medicine
Contact: dcf-support@datacommons.io
ManagedBy: "[Center for Translational Data Science at The University of Chicago](https://ctds.uchicago.edu/)"
UpdateFrequency: |
  Genomic Data Commons (GDC) is the source of truth for this dataset; GDC offers monthly data releases,
  although this dataset may not be updated at every release.
Tags:
  - aws-pds
  - cancer
  - genomic
License: "NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies"
Resources:
  - Description: Biospecimen Supplement, Clinical Supplement
    ARN: arn:aws:s3:::gdc-fm-ad-phs001179-2-open
    Region: us-east-1
    Type: S3 Bucket
DataAtWork:
  Tools & Applications:
    - Title: Genomic Data Commons
      URL: https://portal.gdc.cancer.gov/projects/FM-AD
      AuthorName: National Cancer Institute
      AuthorURL: https://gdc.cancer.gov/
  Publications:
    - Title: |
        High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer
        Pathogenesis
      URL: https://www.ncbi.nlm.nih.gov/pubmed?cmd=DetailsSearch&term=28235761[PMID]
      AuthorName: |
        Ryan J. Hartmaier, Lee A. Albacker, Juliann Chmielecki, Mark Bailey, Jie He, Michael E.
        Goldberg, Shakti Ramkissoon, James Suh, Julia A. Elvin, Samuel Chiacchia, Garrett M.
        Frampton, Jeffrey S. Ross, Vincent Miller, Philip J. Stephens and Doron Lipson
    - Title: |
        Targeted next-generation sequencing of advanced prostate cancer identifies potential
        therapeutic targets and disease heterogeneity.
      URL: https://www.ncbi.nlm.nih.gov/pubmed?cmd=DetailsSearch&term=22981675[PMID]
      AuthorName: |
        Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D,
        Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA